Concomitant NSCLC immunotherapy and beta blocker use offers PFS advantage

  • Clin Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Beta blockers offer protection against disease progression in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for NSCLC.

Why this matters

  • Clinical and preclinical studies of some tumor types have found an association between the use of beta blockers and immunotherapy, but similar studies in patients with lung cancer were lacking.

Study design

  • 109 patients receiving ICIs for NSCLC.
  • Funding: None.

Key results

  • 28 patients received concomitant beta blockers.
  • Patients receiving beta blockers had better PFS (HR, 0.58; 95% CI, 0.36-0.93), but there was no significant difference between groups in OS.
  • No difference in PFS between new or chronic beta blocker users.
  • Patients with intracranial metastases who were receiving beta blockers had better OS (HR, 0.10; 95% CI, 0.04-0.30), but there was no difference in PFS.
  • No significant difference in PFS or OS in patients receiving antidepressants, selective serotonin reuptake inhibitors, or benzodiazepines compared with patients who were not receiving these medications.

Limitations

  • Retrospective study.